Literature DB >> 30703275

Use of antidepressants after colon cancer diagnosis and risk of recurrence.

Gaia Pocobelli1, Onchee Yu1, Rebecca A Ziebell1, Erin J Aiello Bowles1, Monica M Fujii1, Andrew T Sterrett2, Jennifer M Boggs2, Lu Chen1, Denise M Boudreau1,3,4, Debra P Ritzwoller2, Rebecca A Hubbard5, Jessica Chubak1,3.   

Abstract

OBJECTIVE: Prior research examining the association between use of antidepressants after colon cancer diagnosis and risk of recurrence is scant. We evaluated this association among colon cancer patients diagnosed at two integrated health care delivery systems in the United States.
METHODS: We conducted a cohort study of stage I to IIIA colon cancer patients diagnosed at greater than or equal to 18 years of age at Kaiser Permanente Colorado and Kaiser Permanente Washington during 1995 to 2014. We used pharmacy records to identify dispensings for antidepressants and tumor registry records and patients' medical charts to identify cancer recurrences. Using Cox proportional hazards models, we estimated the adjusted hazard ratio (HR) of colon cancer recurrence comparing patients who used antidepressants after diagnosis to those who did not. We also evaluated the risk associated with use of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) separately.
RESULTS: Among the 1923 eligible colon cancer patients, 807 (42%) used an antidepressant after diagnosis and 139 had a colon cancer recurrence during an average 5.6 years of follow-up. Use of antidepressants after colon cancer diagnosis was not associated with risk of recurrence (HR: 1.14; 95% confidence interval [CI], 0.69-1.87). The HR for use of SSRIs was 1.22 (95% CI, 0.64-2.30), and for TCAs, it was 1.18 (95% CI, 0.68-2.07).
CONCLUSIONS: Our findings suggest that use of antidepressants after colon cancer diagnosis was common and not associated with risk of recurrence. Future larger studies with greater power to examine risk associated with individual antidepressants would be valuable additions to the evidence base.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  antidepressants; cohort study; colon cancer; oncology; recurrence; serotonin reuptake inhibitors; tricyclic antidepressants

Mesh:

Substances:

Year:  2019        PMID: 30703275      PMCID: PMC6445707          DOI: 10.1002/pon.5015

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  19 in total

1.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

Review 2.  The use of antidepressants in oncology: a review and practical tips for oncologists.

Authors:  L Grassi; M G Nanni; G Rodin; M Li; R Caruso
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

3.  Antidepressant Use and Risk of Colorectal Cancer in the Women's Health Initiative.

Authors:  Jenna F Kiridly-Calderbank; Susan R Sturgeon; Candyce H Kroenke; Katherine W Reeves
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-22       Impact factor: 4.254

4.  Survival of glioma and colorectal cancer patients using tricyclic antidepressants post-diagnosis.

Authors:  Alex J Walker; Matthew Grainge; Timothy E Bates; Tim R Card
Journal:  Cancer Causes Control       Date:  2012-10-12       Impact factor: 2.506

Review 5.  Evidence report on the occurrence, assessment, and treatment of depression in cancer patients.

Authors:  William F Pirl
Journal:  J Natl Cancer Inst Monogr       Date:  2004

Review 6.  Prevalence of depression in patients with cancer.

Authors:  Mary Jane Massie
Journal:  J Natl Cancer Inst Monogr       Date:  2004

Review 7.  A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients.

Authors:  Saira Sanjida; Monika Janda; David Kissane; Joanne Shaw; Sallie-Anne Pearson; Tracey DiSipio; Jeremy Couper
Journal:  Psychooncology       Date:  2016-01-17       Impact factor: 3.894

8.  Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants.

Authors:  S R Weiss; B H McFarland; G A Burkhart; P T Ho
Journal:  Clin Pharmacol Ther       Date:  1998-05       Impact factor: 6.875

9.  Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement.

Authors:  Jeffrey A Meyerhardt; Pamela B Mangu; Patrick J Flynn; Larissa Korde; Charles L Loprinzi; Bruce D Minsky; Nicholas J Petrelli; Kim Ryan; Deborah H Schrag; Sandra L Wong; Al B Benson
Journal:  J Clin Oncol       Date:  2013-11-12       Impact factor: 44.544

Review 10.  Lifestyle after Colorectal Cancer Diagnosis in Relation to Survival and Recurrence: A Review of the Literature.

Authors:  Moniek van Zutphen; Ellen Kampman; Edward L Giovannucci; Fränzel J B van Duijnhoven
Journal:  Curr Colorectal Cancer Rep       Date:  2017-09-14
View more
  1 in total

Review 1.  Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment.

Authors:  Antonio Asensi-Cantó; María Dolores López-Abellán; Verónica Castillo-Guardiola; Ana María Hurtado; Mónica Martínez-Penella; Ginés Luengo-Gil; Pablo Conesa-Zamora
Journal:  Cancers (Basel)       Date:  2022-07-01       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.